Compare Viatris Inc (VTRS) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Vanguard Value Index Fund ETF — how do they compare? Viatris Inc trades at $17.39 (market cap $20.03B), while Vanguard Value Index Fund ETF trades at $220.24 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 13.1× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| VTRS | VTV | |
|---|---|---|
Market Cap | $20.03B | $262.40B |
Volume | 14,109,977 | 3,293,281 |
Sector | Health | — |
52-Week High | $18.27 | $227.51 |
52-Week Low | $9.74 | $182.86 |
Typical Hold Time | 57 Days | 142 Days |
Enterprise Value | $32.15B | — |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
VTV trades at $219.97, up 0.81% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings but faces selling pressure from institutional indicators. Recent news highlights value stock outperformance in 2026, with VTV beating growth counterparts by significant margins. The fund offers a 2.3% dividend yield and low 0.03% expense ratio, attracting income-focused investors amid market rotation from growth to value strategies.
VTV presents a compelling value proposition with strong 2026 performance and institutional accumulation. However, technical weakness and long-term underperformance versus broad market indices pose risks. The ETF's low-cost structure and dividend yield support defensive positioning, but investors should weigh recent momentum against historical tracking error concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
